1DI BONITO M, COLLINA F, CANTILE M, et al. :Aber- rant expression of cancer stem cells marker prominin-1 in low-grade tubulobular breast Carcinoma: a correlative study between qRT-PCR, flow-cytometric and immunohis- tochemistry analysis [ J]. J Breast Cancer, 2012, 15 (1) : 15-23.
2MIMEAULT M, JOHANSSON S L, BATRA S K. Patho- biological implications of the expression of EGFR, pAkt, NF-KB and MIC-1 in prostate cancer stem cells and their progenies[J]. PLoS One, 2012, 7 (2) : e31919.
3ZHANG L, JIAO M, LI L, et al. Tumorspheres derived from prostate cancer ceils possess chemoresistant and cancer stem cell properties[ J]. J Cancer Res Clin Oneol, 2012, 138 (4) : 675-686.
4BRAWLEY O W. Prostate cancer epidemiology in the U- nited States [ J]. World J Urol, 2012, 30 (2) : 195- 200.
5MALUF F C, SMALETZ O, HERCHENHORN D. Cas- tration-resistant prostate cancer: systemic therapy in 2012 [J]. Clinics (Sao Paulo), 2012, 67 (4) : 389-394.
6NATARAJAN T G, GANESAN N, FITZGERALD K T.Cancer stem cells and markers: new model of tumorigene- sis with therapeutic implications [ J ]. Cancer Biomark, 2011,9 (1-6): 65-99.
7BEDNAR F, SIMEONE D M. Pancreatic cancer stem cell biology and its therapeutic implications [ J ]. J Gas- troenterol, 2011,46 (12) : 1345-1352.
8MO W, ZHANG J T. Human ABCG2: structure, func- tion, and its role in multidrug resistance[J]. IntJ Bio- chem Mol Biol, 2012, 3 (1) : 1-27.
